Archemix’s ARC1779 is currently in Phase II clinical development with a clinical trial designed to assess the safety, pharmacokinetics and pharmacodynamic effects of ARC1779 in approximately 28 patients
Under terms of the definitive agreement, Healthscreen agreed to pay a total of $1.3 million for Regent. Of the purchase price, $1 million has been paid to Regent’s
This multinational Phase II study will evaluate the efficacy of IMC-A12 in adult and adolescent patients with several types of previously treated, advanced or metastatic soft tissue sarcoma,
The first patient has received treatment at Guy’s and St Thomas’s NHS Foundation Trust in London. A total of six patients will be entered into this trial at
SpectraCell’s Lp-PLA2 test measures the amount of a specific enzyme in blood that occurs when there is an active atherosclerotic process that could lead to the rupture of
According to the company, the latest generation of the PressureWire Certus features a new ergonomically designed proximal connector which provides three key advantages for physicians. The new large
HERmark is said to be a proprietary diagnostic that accurately quantifies HER2 total protein levels and HER2 homodimerization in patients with breast cancer. According to the company, HERmark
According to the Financial Times, The National Institute of Health and Clinical Excellence (NICE) has issued a provisional recommendation that Tyverb for advanced breast cancer failed to meet
GlaxoSmithKline (GSK) which currently has 170 R&D staff in China has plans to boost up its staff to 350 by the end of 2009. According to Carol Zhu,
These new data for LifeCycle Pharma (LCP)-Tacro, a once daily immunosuppression drug to prevent rejection after organ transplantation, demonstrated that LCP-Tacro tablets also have a potential best-in-class profile
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.